{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:52:10Z","timestamp":1785523930407,"version":"3.56.0"},"reference-count":17,"publisher":"American Diabetes Association","issue":"8","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,8,1]]},"abstract":"\n OBJECTIVE<\/jats:title>\n We evaluate whether lifestyle and metformin interventions used to prevent diabetes have durable effects on markers of inflammation and coagulation and whether the effects are influenced by the development of diabetes.<\/jats:p>\n <\/jats:sec>\n \n RESEARCH DESIGN AND METHODS<\/jats:title>\n The Diabetes Prevention Program was a controlled clinical trial of 3,234 subjects at high risk for diabetes who were randomized to lifestyle, metformin, or placebo interventions for 3.4 years. Diabetes was diagnosed semiannually by fasting glucose and annually by oral glucose tolerance testing. In addition to baseline testing, anthropometry was performed every 6 months; fasting insulin yearly; and hs-CRP, tissue plasminogen activator (tPA), and fibrinogen at 1 year and end of study (EOS).<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n CRP and tPA levels were unchanged in the placebo group but fell in the lifestyle and metformin groups at 1 year and remained lower at EOS. These reductions were not seen in those who developed diabetes over the course of the study despite intervention. Fibrinogen was lower at 1 year in the lifestyle group. Differences in weight and weight change explained most of the influence of diabetes on the CRP response in the lifestyle group, but only partly in the placebo and metformin groups. Weight, insulin sensitivity, and hyperglycemia differences each accounted for the influence of diabetes on the tPA response.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n Lifestyle and metformin interventions have durable effects to lower hs-CRP and tPA. Incident diabetes prevented these improvements, and this was accounted for by differences in weight, insulin resistance, and glucose levels.<\/jats:p>\n <\/jats:sec>","DOI":"10.2337\/dc13-2471","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T06:02:48Z","timestamp":1400047368000},"page":"2253-2260","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":46,"title":["Lifestyle and Metformin Interventions Have a Durable Effect to Lower CRP and tPA Levels in the Diabetes Prevention Program Except in Those Who Develop Diabetes"],"prefix":"10.2337","volume":"37","author":[{"given":"Ronald B.","family":"Goldberg","sequence":"first","affiliation":[{"name":"Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella G.","family":"Temprosa","sequence":"additional","affiliation":[{"name":"The Biostatistics Center, The George Washington University, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren J.","family":"Mather","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Orchard","sequence":"additional","affiliation":[{"name":"Diabetes and Lipid Research Building, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas E.","family":"Kitabchi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, University of Tennessee, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol E.","family":"Watson","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles, Alhambra, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Diabetes Prevention Program Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,7,12]]},"reference":[{"key":"2022031219542191100_B1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2022031219542191100_B2","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.2337\/diabetes.54.8.2404","article-title":"Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin","volume":"54","author":"Kitabchi","year":"2005","journal-title":"Diabetes"},{"key":"2022031219542191100_B3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","article-title":"Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)","volume":"102","author":"Festa","year":"2000","journal-title":"Circulation"},{"key":"2022031219542191100_B4","doi-asserted-by":"crossref","first-page":"18J","DOI":"10.1016\/S0002-9149(03)00612-X","article-title":"Insulin resistance, inflammation, and the prediabetic state","volume":"92","author":"Haffner","year":"2003","journal-title":"Am J Cardiol"},{"key":"2022031219542191100_B5","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1007\/s00125-005-1938-5","article-title":"Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance","volume":"48","author":"H\u00e4m\u00e4l\u00e4inen","year":"2005","journal-title":"Diabetologia"},{"key":"2022031219542191100_B6","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2337\/diabetes.54.5.1566","article-title":"Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance","volume":"54","author":"Haffner","year":"2005","journal-title":"Diabetes"},{"key":"2022031219542191100_B7","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.2337\/diacare.28.10.2472","article-title":"Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program","volume":"28","author":"Diabetes Prevention Program Research Group","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031219542191100_B8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2337\/diacare.20.7.1183","article-title":"Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","volume":"20","author":"Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"1997","journal-title":"Diabetes Care"},{"key":"2022031219542191100_B9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2337\/diacare.26.4.977","article-title":"Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program","volume":"26","author":"Diabetes Prevention Program Research Group","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031219542191100_B10","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.metabol.2004.06.013","article-title":"Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy","volume":"53","author":"Putz","year":"2004","journal-title":"Metabolism"},{"key":"2022031219542191100_B11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ehj.2003.11.004","article-title":"Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis","volume":"25","author":"Lowe","year":"2004","journal-title":"Eur Heart J"},{"key":"2022031219542191100_B12","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.2337\/dc06-0560","article-title":"Effect of weight loss with lifestyle intervention on risk of diabetes","volume":"29","author":"Hamman","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031219542191100_B13","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.1073\/pnas.97.22.12222","article-title":"Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation","volume":"97","author":"Du","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031219542191100_B14","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2337\/db06-0918","article-title":"Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program","volume":"56","author":"Lachin","year":"2007","journal-title":"Diabetes"},{"key":"2022031219542191100_B15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2003-38386","article-title":"Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro","volume":"35","author":"He","year":"2003","journal-title":"Horm Metab Res"},{"key":"2022031219542191100_B16","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1053\/j.gastro.2006.03.020","article-title":"Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1","volume":"130","author":"Bergheim","year":"2006","journal-title":"Gastroenterology"},{"key":"2022031219542191100_B17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc08-0494","article-title":"Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group","volume":"32","author":"Goldberg","year":"2009","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/8\/2253\/622674\/2253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/8\/2253\/622674\/2253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T21:39:08Z","timestamp":1647121148000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/37\/8\/2253\/29547\/Lifestyle-and-Metformin-Interventions-Have-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,12]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,7,12]]},"published-print":{"date-parts":[[2014,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc13-2471","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,12]]}}}